Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
RESEARCH TOOLSreports
Holding TSHA?
Track your performance easily
TSHA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.19 - $4.32
Previous CloseN/A
Volume273.02K
Average Volume (3M)2.82M
Market Cap
$323.81M
Enterprise Value$442.73M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Mar 26, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding204,943,310
10 Day Avg. Volume2,337,951
30 Day Avg. Volume2,815,098
Standard Deviation0.60
R-Squared0.00522
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)32.64
Price to Cash Flow (P/CF)-3.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue44.63
Enterprise Value/Gross Profit28.65
Enterprise Value/Ebitda-25.91
Forecast
1Y Price Target
$6.61Price Target Upside332.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Taysha Gene Therapies News
PremiumCompany Announcements
Taysha Gene Therapies Advances in Rett Syndrome Trials
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentTSHA-102's clinical benefit in Rett syndrome will become increasingly apparent, given the meaningful unmet need in this disease.
Investment OpportunityThe recent pullback in TSHA provides a good entry point for investors heading into the year.
Regulatory AlignmentThere is already alignment with the FDA on the final commercial manufacturing process, which will be used starting in Part B.
Bears Say
Clinical Data UncertaintyThe recent stock reaction following initial pediatric data and longer-term adolescent/adult data for TSHA-102 has raised questions around clinical benefit and approvable endpoints.
Competitive PositioningThere is no clear winner based on clinical data so far, indicating uncertainty in TSHA's competitive standing.
Financial PerformanceNet loss per share was ($0.10) vs. consensus of ($0.09).
---
Ownership Overview
16.20% Insiders
13.63% Mutual Funds
<0.01% Other Institutional Investors
60.50% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TSHA FAQ
What was Taysha Gene Therapies’s price range in the past 12 months?
Taysha Gene Therapies lowest stock price was $1.19 and its highest was $4.32 in the past 12 months.
What is Taysha Gene Therapies’s market cap?
Taysha Gene Therapies’s market cap is $323.81M.
When is Taysha Gene Therapies’s upcoming earnings report date?
Taysha Gene Therapies’s upcoming earnings report date is Mar 26, 2025 which is in 66 days.
How were Taysha Gene Therapies’s earnings last quarter?
Taysha Gene Therapies released its earnings results on Nov 13, 2024. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.087 by -$0.013.
Is Taysha Gene Therapies overvalued?
According to Wall Street analysts Taysha Gene Therapies’s price is currently Undervalued.
Does Taysha Gene Therapies pay dividends?
Taysha Gene Therapies does not currently pay dividends.
What is Taysha Gene Therapies’s EPS estimate?
Taysha Gene Therapies’s EPS estimate is -0.08.
How many shares outstanding does Taysha Gene Therapies have?
Taysha Gene Therapies has 204,943,310 shares outstanding.
What happened to Taysha Gene Therapies’s price movement after its last earnings report?
Taysha Gene Therapies reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.087. Following the earnings report the stock price went up 2.715%.
Which hedge fund is a major shareholder of Taysha Gene Therapies?
Currently, no hedge funds are holding shares in TSHA
---
Taysha Gene Therapies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.61 (332.03% Upside)
$6.61 (332.03% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 28.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.47%
12-Months-Change
Fundamentals
Return on Equity
-114.77%
Trailing 12-Months
Asset Growth
-7.94%
Trailing 12-Months
Company Description
Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
---
TSHA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in the TSHA-102 program, regulatory progress, a strong safety profile, and financial stability, despite an increase in R&D expenses. The overall sentiment is positive due to the outweighed highlights.Read More>---
TSHA Stock 12 Month Forecast
Average Price Target
$6.61
▲(332.03% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Fate Therapeutics
―
Meiragtx Holdings
―
Bluebird Bio
―
Sangamo Biosciences
―
Intellia Therapeutics
―
Best Analysts Covering TSHA
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
+22.08%
assigned a buy rating 2 months ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +22.08% per trade.
---